Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Xencor (XE9) Stock Price & Analysis

XE9 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 1.83B
Enterprise Value
CHF 934.98M
Total Cash (Recent Filing)
CHF 456.45M
Total Debt (Recent Filing)
CHF 65.21M
Price to Earnings (P/E)
―
Beta
1.61
Next Earnings
Nov 09, 2026 (Est.)
EPS Estimate
-0.28
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

XmAb Platform

The XmAb platform provides a reusable antibody-engineering foundation across cancer and autoimmune or inflammatory programs. Its ability to enhance immune activity, half-life, and multispecific binding can support differentiated candidates and partnership opportunities over multiple development cycles.

XmAb819 Pipeline Progress

Encouraging Phase 1 activity and a defined proposed Phase 3 dose improve visibility for XmAb819, while planned FDA discussions and a randomized study create a potential path toward registration. Advancement would strengthen the pipeline and could expand future partnering or royalty opportunities.

Non-dilutive Capital

The settlement supplies substantial non-dilutive capital and restores management's stated runway through 2028, reducing near-term financing pressure. Retained ex-U.S. royalties also preserve an ongoing international revenue stream, supporting flexibility while clinical programs advance.

Bears Say

Persistent Losses

Sizable net losses and deeply negative operating results show that current development spending is not yet supported by recurring earnings. Continued losses can erode the capital base and leave future financial performance dependent on successful clinical progress, partnerships, or additional funding.

Ongoing Cash Burn

Persistent negative operating and free cash flow indicates the business remains far from self-funding. Even with the settlement-supported runway, continued cash consumption may require disciplined spending and could eventually increase reliance on milestone receipts, royalties, partnerships, or financing.

Revenue Volatility

A volatile revenue profile makes it difficult to establish dependable earnings power, particularly for a company relying on collaborations, licensing, milestones, and royalties. Uneven receipts can complicate planning and leave results exposed to the timing of partner-driven development and commercial events.

Xencor News

XE9 FAQ

What is Xencor’s market cap?
Xencor’s market cap is CHF1.83B.
When is Xencor’s upcoming earnings report date?
Xencor’s next earnings report is estimated for Nov 09, 2026 (not yet confirmed), which is in 7 days.
How were Xencor’s earnings last quarter?
Xencor released its earnings results on Aug 05, 2026. The company reported -CHF0.239 earnings per share for the quarter, beating the consensus estimate of -CHF0.661 by CHF0.421.
Is Xencor overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Xencor pay dividends?
Xencor does not currently pay dividends.
What is Xencor’s EPS estimate?
Xencor’s EPS estimate is -0.28.
How many shares outstanding does Xencor have?
Xencor has 74,353,390 shares outstanding.
What happened to Xencor’s price movement after its last earnings report?
Xencor reported an EPS of -CHF0.239 in its last earnings report, beating expectations of -CHF0.661. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Xencor?
Hedge funds hold Xencor shares: the largest hedge-fund position in Xencor is 1,770,470,054 shares, and hedge funds increased their holdings by 227.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology